Clinical Trials Logo

Fetal Death clinical trials

View clinical trials related to Fetal Death.

Filter by:

NCT ID: NCT05365464 Withdrawn - Clinical trials for Recurrent Pregnancy Loss Without Current Pregnancy

HOPE Trial hCG or Progesterone Effect on Recurrent Pregnancy Loss

HOPE
Start date: May 2022
Phase: Phase 2
Study type: Interventional

Up to half of all cases of recurrent pregnancy loss are unexplained (uRPL). Evidence points towards endometriosis and progesterone resistance as an underlying cause of uRPL. Previous non-RCT studies have suggested the luteal hCG provides a useful treatment for uRPL. We propose performing a randomized controlled trial to compare mid-luteal hCG with oral progesterone to prevent early pregnancy losses. the endpoint will be ongoing pregnancy and live birth rates. Equal numbers of patients will be randomized to each group.

NCT ID: NCT05342948 Completed - Clinical trials for Recurrent Pregnancy Loss

Association of HY-restricting HLA Class II Alleles, Sex of Firstborn Child, and Pregnancy Outcome in RPL Patients

Start date: January 1, 2016
Phase:
Study type: Observational [Patient Registry]

This cross-sectional and prospective cohort study will investigate if sRPL patients with a first born boy who carry ≥1 HY-restricting (HY-r) HLA class II alleles are associated with a lower chance for a succesful reproductive outcome in first pregnancy after admission compared to sRPL patients with a first born girl carrying ≥1 HY-r HLA class II alleles and women with no HY-r HLA class II alleles and a firstborn boy. Also, the study will compare sRPL patients with a firstborn boy who do not carry a HY-r HLA class II allele with sRPL patients having a firstborn girl and carrying no such alleles. We hypothesize that sRPL patients with a first born boy compared to sRPL patients with a firstborn girl who carry ≥1 HY-r HLA class II alleles is associated with a negative prognosis, while no association between sex of firstborn child and pregnancy outcome is expected in sRPL carrying no HY-r HLA class II alleles. Neither do we expect an association between pregnancy outcome and carriage of HY-r HLA class II alleles in pRPL patients.

NCT ID: NCT05340556 Recruiting - Clinical trials for Recurrent Pregnancy Loss, Not Pregnant

Microchimerism in Patients With Recurrent Pregnancy Losses

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

This pilot study aims to evaluate if microchimeric cells in a patient with recurrent pregnancy loss (RPL) can be detected by the blood analysis for the presence of the DYS14 gene and the use of indel-panel methods and also, to examine if this method can distinguish the cell's origin; comparing gene sequence from the patient's firstborn son or her older brother. In addition, the pilot study will provide the investigators with information and experience necessary for a subsequent main study to be conducted.

NCT ID: NCT05322252 Recruiting - Clinical trials for Pregnancy Complications

Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial

MIST
Start date: July 1, 2022
Phase: Phase 4
Study type: Interventional

When time allows, administration of mifepristone prior to second trimester induction of labor decreases total labor time. However, in the setting of many pregnancy complications, decreasing time from diagnosis of nonviable pregnancy to delivery is of utmost importance to decrease risk of maternal complications. Previous data has shown that total abortion time is longer in the group receiving mifepristone owing to the delay between mifepristone administration and initiation of misoprostol induction of labor. Thus, the investigators aim to investigate whether simultaneous mifepristone and misoprostol has benefits over misoprostol alone when labor induction of a nonviable second trimester cannot be delayed.

NCT ID: NCT05237843 Not yet recruiting - Clinical trials for Recurrent Pregnancy Loss

Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss

Start date: March 1, 2022
Phase: Phase 1
Study type: Interventional

To investigate efficacy and safety of Hydroxychloroquin in improving pregnancy outcome in women with unexplained recurrent pregnancy loss .

NCT ID: NCT05205044 Completed - Clinical trials for Recurrent Pregnancy Loss

Evaluation of Apelin-13 and Apelin-36 in Women With Recurrent Pregnancy Loss

Start date: January 23, 2022
Phase:
Study type: Observational

Lower Apelin levels are associated with hypertensive disorders with pregnancy, yet no studies investigated its levels in recurrent pregnancy loss

NCT ID: NCT05073978 Completed - Preterm Birth Clinical Trials

B-vitamin Levels and Adverse Pregnancy Outcomes

Start date: December 1, 2020
Phase:
Study type: Observational

This prospective nested case-control study aims to examine the effects of blood vitamin B levels in first-trimester pregnant women on the pregnancy outcomes

NCT ID: NCT05039853 Not yet recruiting - Clinical trials for Post-traumatic Stress Disorder

Improving Mental Health Following Early PREgnancy Loss Using a Brief Cognitive Task

IMPREL
Start date: October 2021
Phase: N/A
Study type: Interventional

This is a randomised controlled trial designed to investigate the impact of a brief-cognitive task based intervention on intrusive memories, mental health symptoms and daily functioning, in women following an early pregnancy loss.

NCT ID: NCT04935138 Terminated - Clinical trials for Early Pregnancy Loss

Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy Loss

Start date: June 1, 2021
Phase:
Study type: Observational

The study assesses the accuracy of cell-free DNA (cfDNA) analysis in detecting whole chromosomal aneuploidies from maternal plasma of patients with early, missed miscarriage.

NCT ID: NCT04718233 Completed - Clinical trials for Recurrent Pregnancy Loss

Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss

Start date: September 5, 2018
Phase: Phase 2
Study type: Interventional

Patients with recurrent pregnancy loss are known to have decreased uterine artery blood flow. Nitric oxide plays a major role in increasing uterine blood flow during the luteal phase. This study is done to evaluate the effects of sildenafil on blood flow indices in the patients with recurrent pregnancy loss due to impaired uterine artery blood flow.